Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 3Phase 1/2 3Phase 1 2Phase 2/3 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Multiple Myeloma 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Recurrence 9Burkitt Lymphoma 7Neoplasms, Plasma Cell 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma 5Immunoglobulin Light-chain Amyloidosis 5Hodgkin Disease 4Lymphoma, T-Cell 3Lymphoma, Non-Hodgkin 3Lymphoma, B-Cell 3Leukemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Oligodendroglioma 2Neoplasms 2Neoplasm Metastasis 2Mesothelioma 2Lymphoma, T-Cell, Cutaneous 2Leukemia, Myeloid, Acute 2Leukemia, Hairy Cell 2Leukemia, Biphenotypic, Acute 2Hematologic Neoplasms 2Glioblastoma 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Astrocytoma 2Amyloidosis 2Waldenstrom Macroglobulinemia 1Vascular Diseases 1Uveal Melanoma 1

Interventions

Cyclophosphamide 15fludarabine phosphate 11Bortezomib 8Filgrastim 7fludarabine 6Vorinostat 6Etoposide 6tanespimycin 5Prednisone 5Peripheral Blood Stem Cell Transplantation 5Doxorubicin 5Busulfan 5aldesleukin 4Vincristine 4Tacrolimus 4Paclitaxel 4Lenalidomide 4Gemcitabine 4sargramostim 3nelarabine 3Whole-Body Irradiation 3Topotecan 3Leucovorin 3Irinotecan 3Fluorouracil 3Everolimus 3Dexamethasone 3Dasatinib 3Cytarabine 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Calcium Dobesilate × Clear all
NCT04681105 2026-01-28

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

City of Hope Medical Center

Phase 1 Completed
13 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Mastocytosis, Systemic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01363817 2019-07-30

Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Bristol-Myers Squibb

Phase 1 Completed
31 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡